Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Hørsholm, Denmark, August 19, 2021 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby announces that the company's Board and Management intend to fully exercise their TO5 holdings during the subscription period in September 2021. This confirms the company's Board and Management's full commitment and confidence in ExpreS2ion's ongoing transition into a pipeline-driven company with high-value assets such as its COVID-19 and HER2 breast cancer vaccine candidates.
CEO Bent Frandsen comments:
"I am proud to announce that ExpreS[2]ion's Board of Directors and Management have unanimously agreed to fully exercise all of our TO5 warrants. Collectively, our holdings amount to 65,142 TO5 warrants, representing 1.2% of the total outstanding TO5 warrants. Our participation reflects our full commitment to the direction of the company, including the transition to a pipeline driven strategy, as well as the potential for our leading COVID-19 and HER2 breast cancer vaccine candidates."
More information on the TO5 warrant exercise, including the exercise price issue size and dilution, will be published ahead of the warrant subscription period, which is from September 6 to September 20, 2021.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 11 32 30 732
E-mail: ca@skmg.se
This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out below, at the time stated by the Company's news distributor, Cision, at the publication of this press release.